Strategic Advancements and Market Potential Drive Buy Rating for Mediwound

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Mediwound (MDWD – Research Report). The associated price target remains the same with $25.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Mediwound’s strategic advancements and market potential. The company is making significant progress with its EscharEx product, which is currently undergoing a Phase 3 VALUE study for venous leg ulcers (VLU). This study is designed to have a high probability of success, and Mediwound plans to conduct a Phase 2 study to compare EscharEx with existing collagenase products, potentially increasing its market adoption.
Moreover, Mediwound is expanding the use of EscharEx for diabetic foot ulcers (DFU) with plans for a Phase 2/3 study, supported by substantial funding from the European Innovation Council. Additionally, a new Medicare policy update could favorably impact EscharEx adoption by emphasizing the importance of complete wound debridement. The demand for Mediwound’s NexoBrid product is also strong, with plans to increase production capacity, further supporting the company’s growth prospects.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.